Merck Sharp & Dohme
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Merck Sharp & Dohme sits in the top decile of US sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count).
Merck Sharp & Dohme: 558 sponsored US clinical trials, 120 recruiting.
Merck Sharp & Dohme sponsors 558 registered US clinical trials on ClinicalTrials.gov, 120 of them currently recruiting, and 320 completed. 191 of these trials are in Phase 3-4 (later-stage) and 360 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 25 trials.
Top-decile sponsor footprint
Merck Sharp & Dohme ranks in the top decile of sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
320 of 354 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
558 total, page 11 of 12
Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)
NCT01736683
A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)
NCT01446003
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma
NCT01370317
A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)
NCT01235728
A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)
NCT01220258
Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors
NCT01190644
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)
NCT01105624
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease
NCT01014078
Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)
NCT00931606
The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)
NCT00894530
The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period
NCT00892970
A Study of Aprepitant (MK-0869) in Pediatric Participants Undergoing Surgery (MK-0869-148)
NCT00819039
Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis
NCT00656539
Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis
NCT00629941
Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis
NCT00629590
Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers
NCT00575367
Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis
NCT00629980
Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease
NCT00625612
Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery
NCT00575380
Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis
NCT00534794
A Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis
NCT00407927
Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin
NCT00395421
A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011)
NCT00397683
Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea
NCT00392574
Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Grafting (CABG) Involving Cardiopulmonary Bypass
NCT00316212
A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C
NCT00118768
A Study in Pediatric Patients With Cystic Fibrosis Lung Disease
NCT00130182
Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)
NCT00110188
Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy
NCT00120861
Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers
NCT00099450
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
NCT00105469
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
NCT00105534
Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C
NCT00120835
Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)
NCT00087451
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
NCT00086125
Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment
NCT00083967
Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)
NCT00060645
Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C
NCT00227435
MARS - Monitored Atherosclerosis Regression Study
NCT00116870
A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine
NCT00000628
A Study of the Side Effects of L-743,872 in Men With Candidal Esophagitis
NCT00005921
The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz
NCT00002387
A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC
NCT00002155
Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors
NCT00002361
A Study of L-735,524 in HIV-Positive Children and Adolescents
NCT00002351
Safety and Effectiveness of Giving Indinavir and Nelfinavir to HIV-Infected Patients
NCT00002375
A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients
NCT00002354
A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations
NCT00002430
A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC
NCT00002208
A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients
NCT00002406
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 230 |
| Phase 2 | 130 |
| Phase 3 | 173 |
| Phase 4 | 18 |
Therapeutic Areas
What is open in the Merck Sharp & Dohme pipeline
120 recruiting of 558 indexed (22% open); 320 completed (57%).
Phase mix: 191 late (III/IV) vs 360 early (I/II) (early-phase heavy).
Top condition: Healthy (25 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Merck Sharp & Dohme: open-pipeline peers nationwide
Peers matched on 558 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
Merck Sharp & Dohme sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 558 trials (± recruiting share)
- Amgen · 558 trials · 10% recruiting
- Virginia Commonwealth University · 558 trials · 14% recruiting
- University of Maryland, Baltimore · 560 trials · 18% recruiting
- Ohio State University · 552 trials · 21% recruiting
Sponsors near 22% open enrollment (± trial volume)
- AbbVie · 21% recruiting · 526 trials
- Women and Infants Hospital of Rhode Island · 22% recruiting · 65 trials
- Florida State University · 21% recruiting · 219 trials
- Axsome Therapeutics · 21% recruiting · 28 trials
Related
What to do with this Merck Sharp & Dohme page
558 registered trials is a research-attention snapshot, not an endorsement of Merck Sharp & Dohme or any single study.
- 120 of Merck Sharp & Dohme's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Merck Sharp & Dohme studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Merck Sharp & Dohme pipeline card: 558 registered trials from official public datasets.Report a data error.